Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine

Inclusion Criteria: * Healthy adult males or females 18-49 years of age (inclusive) * signed Informed Consent * Women who are not post-menopausal or surgically sterile must have a negative serum or urine pregnancy test at screening and at all in-clinic visits with understanding to not become pregnant over the duration of the study. Exclusion Criteria: * Clinically significant laboratory abnormalities at screening * abnormalities at physical examination * known allergies to any component of the A/H5N1 antigen * known egg protein allergy * known allergies to adhesives * known coagulation disorders * use of any anticoagulant medication within 30 days prior to vaccination or planned usage during the study period * participated in research involving investigational product within 30 days before planned date of vaccination or planned participation during study period * donated or received blood or blood products such as plasma within the three months before planned date of vaccination or planned donation or use during the study period * received or planned receipt of seasonal influenza vaccine during the study period * received any licensed vaccines within 2 weeks (inactivated vaccines) or 4 weeks (live vaccines) prior to planned date of vaccination * planned receipt of any licensed vaccine during the first 42 days on study * previous or planned vaccination with any vaccine containing an oil in water emulsion adjuvant * previous or planned vaccination with pandemic vaccine against A/H5N1 or previous proven contact with A/H5N1 wild type virus * ever received investigational enterotoxigenic E. coli LT, or LT (R192G) or NasalFlu, Berna Biotech, Ltd. Ever received cholera toxin or vaccine * Recent or regular use of oral, topical or injected steroid medications within 30 days prior to vaccination or planned use during the study period. * Use of immunosuppressive systemic steroid medications including inhaled steroids within three months prior to vaccination or planned use during the study period * Comorbid conditions or treatments that are immunosuppressive, including cancer, diabetes, and end-stage renal disease, as determined by the Investigator * positive serology for HIV-1, HIV-2, HBsAg, or HCV * history of severe atopy * medical history of acute or chronic skin disease at vaccination area * active skin allergy * signs of acute skin infection, sunburn or skin abnormalities at the vaccination area including fungal infections, severe acne, active contact dermatitis, or a history of keloid formation * hirsute at vaccination area * artificial tanning over the duration of the study including the screening period * visible tattoos or marks at the vaccination area that would prevent appropriate dermatologic monitoring of the vaccination site * fever greater than or equal to 38.0°C at the time of planned vaccination * suspicion of or recent history of alcohol or substance abuse * women who are pregnant or breastfeeding * acute illness at screening or at the time of planned vaccination * ever had a serious reaction to prior influenza vaccination * developed a neurological disorder following a previous influenza vaccination or have any acute and evolving neurological disorder * employee of the investigational site or sponsor * history of employment in bird or poultry industries or considerable exposure to birds